...
首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >In vitro-formulated oligomers of strep-tagged avian influenza haemagglutinin produced in plants cause neutralizing immune responses
【24h】

In vitro-formulated oligomers of strep-tagged avian influenza haemagglutinin produced in plants cause neutralizing immune responses

机译:植物产生的带有链球菌标签的禽流感血凝素的体外配制低聚物可引起中和性免疫反应

获取原文
           

摘要

The worldwide emergence of the novel influenza A H5N1 and H5N8 has notably and directly impacted the poultry industry, resulting in the need for effective and cheap vaccination strategies to protect poultry worldwide. Subunit vaccines from plants can be produced for a low cost, and plant production systems are easily scaled up at low infrastructure cost. However, subunit vaccines generally induce low immunogenicity against influenza. To address this issue, we present a new and innovative method to generate highly immunogenic H5 oligomers. The method is based on specific and high-affinity interaction between engineered streptavidin (Strep-Tactin? XT) and the Strep-tag II peptide. H5-Strep-tag II-tagged trimers were produced via transient agroinfection in tobacco leaves and purified, and oligomers were formulated in vitro by adding purified homotetrameric Strep-Tactin? XT. Immunogenicity was tested by performing mouse immunizations. Haemagglutinin oligomers produced in vitro by combining Strep-Tactin? XT and Strep-tag II-fused haemagglutinin trimers from plants raised potentially neutralizing antibodies in mice. Vaccines based on actual H5N1 haemagglutinin can be produced by combining strep-tagged haemagglutinin trimers from plants and Strep-Tactin? XT.
机译:新型甲型H5N1和H5N8流感病毒在全球范围内的出现特别直接地影响了家禽业,因此需要有效且廉价的疫苗接种策略来保护全世界的家禽。来自植物的亚单位疫苗可以低成本生产,而植物生产系统可以轻松地以较低的基础设施成本扩大规模。然而,亚单位疫苗通常诱导针对流感的低免疫原性。为解决此问题,我们提出了一种新的创新方法来生成高度免疫原性的H5低聚物。该方法基于工程化的链霉亲和素(Strep-Tactin?XT)与Strep-tag II肽之间的特异性和高亲和力相互作用。 H5-Strep-tag II-标记的三聚体是通过短暂的农杆菌感染在烟叶中产生并纯化的,并通过加入纯化的同四聚体Strep-Tactin?体外配制寡聚体。 XT。通过进行小鼠免疫来测试免疫原性。血凝素寡聚体是通过结合Strep-Tactin?体外产生的?来自植物的XT和与Strep-tag II融合的血凝素三聚体在小鼠中产生了潜在的中和抗体。基于实际H5N1血凝素的疫苗可以通过将来自植物的带有strep标记的血凝素三聚体和Strep-Tactin?结合而生产。 XT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号